Literature DB >> 14560921

Anti-tumor activities of decursinol angelate and decursin from Angelica gigas.

Sanghyun Lee1, Yeon Sil Lee, Sang Hoon Jung, Kuk Hyun Shin, Bak-Kwang Kim, Sam Sik Kang.   

Abstract

The in vivo anti-tumor activities of decursinol angelate (1) and decursin (2) isolated from the roots of Angelica gigas were investigated. These two compounds, when administered consecutively for 9 days at 50 and 100 mg/kg i.p. in mice, caused a significant increase in the life span and a significant decrease in the tumor weight and volume of mice inoculated with Sarcoma-180 tumor cells. These results suggest that decursinol angelate (1) and decursin (2) from A. gigas have anti-tumor activities.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14560921     DOI: 10.1007/bf02976682

Source DB:  PubMed          Journal:  Arch Pharm Res        ISSN: 0253-6269            Impact factor:   4.946


  27 in total

1.  In vitro metabolism of pyranocoumarin isomers decursin and decursinol angelate by liver microsomes from man and rodents.

Authors:  Li Li; Jinhui Zhang; Chengguo Xing; Sung-Hoon Kim; Cheng Jiang; Junxuan Lü
Journal:  Planta Med       Date:  2013-09-11       Impact factor: 3.352

2.  The Neuroprotective Effects of Decursin Isolated from Angelica gigas Nakai Against Amyloid β-Protein-Induced Apoptosis in PC 12 Cells via a Mitochondria-Related Caspase Pathway.

Authors:  Li Li; Jikun Du; Liyi Zou; Haishan Xia; Tie Wu; Yongho Kim; Yongwoo Lee
Journal:  Neurochem Res       Date:  2015-06-16       Impact factor: 3.996

3.  Inhibition of cyclooxygenase-2-dependent survivin mediates decursin-induced apoptosis in human KBM-5 myeloid leukemia cells.

Authors:  Quein Ahn; Soo-Jin Jeong; Hyo-Jung Lee; Hee-Young Kwon; Ihn Han; Hyun Seok Kim; Hyo-Jeong Lee; Eun-Ok Lee; Kwang Seok Ahn; Min-Hyung Jung; Shudong Zhu; Chang-Yan Chen; Sung-Hoon Kim
Journal:  Cancer Lett       Date:  2010-07-31       Impact factor: 8.679

4.  Pyranocoumarin Tissue Distribution, Plasma Metabolome and Prostate Transcriptome Impacts of Sub-Chronic Exposure to Korean Angelica Supplement in Mice.

Authors:  Jinhui Zhang; Li Li; Suni Tang; Yong Zhang; Maciej Markiewski; Chengguo Xing; Cheng Jiang; Junxuan Lü
Journal:  Am J Chin Med       Date:  2016       Impact factor: 4.667

5.  Prostate Cancer Xenograft Inhibitory Activity and Pharmacokinetics of Decursinol, a Metabolite of Angelica gigas Pyranocoumarins, in Mouse Models.

Authors:  Wei Wu; Su-Ni Tang; Yong Zhang; Manohar Puppala; Timothy K Cooper; Chengguo Xing; Cheng Jiang; Junxuan Lü
Journal:  Am J Chin Med       Date:  2017-11-09       Impact factor: 4.667

6.  Cancer Chemoprevention with Korean Angelica: Active Compounds, Pharmacokinetics, and Human Translational Considerations.

Authors:  Junxuan Lü; Jinhui Zhang; Li Li; Cheng Jiang; Chengguo Xing
Journal:  Curr Pharmacol Rep       Date:  2015-04-19

7.  A synthetic decursin analog with increased in vivo stability suppresses androgen receptor signaling in vitro and in vivo.

Authors:  Yong Zhang; Ahmad Ali Shaik; Chengguo Xing; Yubo Chai; Li Li; Jinhui Zhang; Wei Zhang; Sung-Hoon Kim; Junxuan Lü; Cheng Jiang
Journal:  Invest New Drugs       Date:  2011-08-26       Impact factor: 3.850

8.  Ultrafine Angelica gigas powder normalizes ovarian hormone levels and has antiosteoporosis properties in ovariectomized rats: particle size effect.

Authors:  Kyeong-Ok Choi; Inae Lee; Sae-Yeol-Rim Paik; Dong Eun Kim; Jung Dae Lim; Wie-Soo Kang; Sanghoon Ko
Journal:  J Med Food       Date:  2012-10       Impact factor: 2.786

9.  Decursin from Angelica gigas Nakai Inhibits B16F10 Melanoma Growth Through Induction of Apoptosis.

Authors:  Byung Soo Kim; Hyobin Seo; Ha-Jeong Kim; Sang Mun Bae; Hye-Nam Son; Yoon Jeong Lee; Sungpil Ryu; Rang-Woon Park; Ju-Ock Nam
Journal:  J Med Food       Date:  2015-09-03       Impact factor: 2.786

10.  Decursin inhibits retinal neovascularization via suppression of VEGFR-2 activation.

Authors:  Jeong Hun Kim; Jin Hyoung Kim; You Mie Lee; Eun-Mi Ahn; Kyu-Won Kim; Young Suk Yu
Journal:  Mol Vis       Date:  2009-09-12       Impact factor: 2.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.